The UK and US have secured a landmark commercial pact that will maintain zero import taxes on UK medicine shipments entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the NHS. This commitment ensures that import taxes on these vital products will remain at zero for a duration of three years.
This development is in response to earlier statements to hike tariffs on patented drug products, with increases discussed as high as double the cost.
"This agreement with the UK reinforces the global environment for cutting-edge drugs and brings long-overdue equity to transatlantic medicine commerce," an announcement declared.
Commercial Impact
Drugs constitute one of the Britain's largest goods shipped to the America, which is clearly the biggest market for major UK drugmakers.
Statistics reveal that in the year leading up to September, the UK sold pharmaceutical products valued at billions to the US. This figure accounted for 17.4% of British export trade in that span.
"This guarantee safeguards work, increases capital expenditure and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The agreement involves several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be capped at 15%. In the past, repayments topped 20%.
Recent Tensions
The pact comes amid a long-running tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
This friction were intensified by arguments that US patients were paying a premium for the same drugs than patients in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward American operations.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a proportion of its resources over the previous ten-year period.
